ChinaBio Partnering Forum 2016 Showcases SIP’s Joined-up Thinking Across Pharma Industry | Be Korea-savvy

ChinaBio Partnering Forum 2016 Showcases SIP’s Joined-up Thinking Across Pharma Industry

(image: Suzhou Industrial Park)

(image: Suzhou Industrial Park)


SUZHOU, China, May 23 (Korea Bizwire) — Suzhou Industrial Park played host to world-leading pharmaceutical companies and venture capitalists at the ChinaBio Partnering Forum 2016 on May 18, helping to optimize the innovation and capital chains of the life-sciences ecosystem in the region.

It is the fourth time the forum – which is the biggest event of its kind in China – has been held since its inaugural event in 2009.

Over 1,000 industry players attended the forum, with high-level representatives from giants such as Bayer, AstraZeneca, Johnson & Johnson, Hanmi Pharmaceutical, Wuxi AppTech, Jiangsu Heng Rui Medicine, Cooley LLP, OrbiMed Healthcare Fund Management and BayHelix Group.

The event was organized by BioBAY, a nexus for more than 400 high-tech innovative companies covering drug discovery, medical devices, biotech, CRO and nanotech. It has thus far attracted some 10,000 scientists and professionals to its dynamic community.

Attendees at this year’s forum said one of the most valuable features of the gathering was how it facilitated one-to-one meetings between stakeholders, and particularly between firms local to SIP and institutions from further afield.

Mr. Pang Junyong, CEO of BioBAY, explained the philosophy behind the event and BioBAY’s wider strategy. “It’s imperative to have a ‘cross-disciplinary’ mindset for any modern industrial chain to succeed,” said Mr. Pang. “That’s why we at BioBAY have been dedicated to taking a more international perspective when it comes to improving the quality of our service offerings to our partners. This will also help bring the competitiveness of the whole region’s bio and nanotech sectors to new heights.”

Recent outcomes of the full-chain, cross-sector approach pioneered by SIP and BioBAY include the recent Nasdaq filings by BioBAY tenants Hutchison Medi Pharma and BeiGene. The latter recently listed, securing funding of USD 158 million.

Meanwhile, BioBAY tenant ZAI Lab has secured funding of USD 100 million, while also forging a partnership with Korea-based pharma giant Hanmi Pharmaceutical Co.

Vivian Ren, Suzhou Industrial Park Administrative Committee News Center
86- 512-66681834

Lan Shen, Z. H. STUDIO

Source: Suzhou Industrial Park via GLOBE NEWSWIRE

press release curation and disclaimer notice

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>